We are analyzing https://link.springer.com/article/10.1007/s11010-022-04492-3.

Title:
Rheumatoid arthritis: advances in treatment strategies | Molecular and Cellular Biochemistry
Description:
Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to heightened autoimmune response at the articular sites. Worldwide annual incidence and prevalence rate of RA is 3 cases per 10,000 population and 1%, respectively. Several genetic and environmental (microbiota, smoking, infectious agents) factors contribute to its pathogenesis. Although convention treatment strategies, predominantly Disease Modifying Anti Rheumatic Drugs (DMARDs) and Glucocorticoids (GC), are unchanged as the primary line of treatment; novel strategies consisting of biological DMARDs, are being developed and explored. Personalized approaches using biologicals targetspecific pathways associated with disease progression. However, considering the economic burden and side-effects associated with these, there is an unmet need on strategies for early stratification of the inadequate responders with cDMARDs. As RA is a complex disease with a variable remission rate, it is important not only to evaluate the current status of drugs in clinical practice but also those with the potential of personalised therapeutics. Here, we provide comprehensive data on the treatment strategies in RA, including studies exploring various combination strategies in clinical trials. Our systematic analysis of current literature found that conventional DMARDs along with glucocorticoid may be best suited for early RA cases and a combination of conventional and targeted DMARDs could be effective for treating seronegative patients with moderate to high RA activity. Clinical trials with insufficient responders to Methotrexate suggest that adding biologicals may help in such cases. However, certain adverse events associated with the current therapy advocate exploring novel therapeutic approaches such as gene therapy, mesenchymal stem cell therapy in future.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Education
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,642,828 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

article, arthritis, google, scholar, rheumatoid, cas, patients, treatment, methotrexate, httpsdoiorgs, rheum, study, rheumatol, dis, ther, clinical, therapy, response, review, ann, safety, cell, trial, results, phase, manuscript, rheumatology, strategies, drugs, res, clin, httpsdoiorgart, active, httpsdoiorg, efficacy, adalimumab, early, med, httpsdoiorgannrheumdis, synovial, abatacept, rituximab, analysis, disease, dmards, smolen, rev, immunol, front, inhibitors,

Topics {✒️}

shivani arora mittal /cochrane/clcentral/articles/205/cn-01524205/frame granulocyte-macrophage colony-stimulating factor enhances tnf-α-induced icam-1 humanized anti-il-6r antibody tumor necrosis factor-α histone deacetylase/acetylase activity hypothalamus-pituitary-adrenal axis anti-tnf induced sarcoidosis month download article/chapter investigator-initiated clinical trial nirmal kumar ganguly phase iiib/iv trial fda-approved jak inhibitor long-term extension study mir-124a inhibits proliferation real-world treatment patterns rheumatoid arthritis hla-dr4 anti-rankl antibody denosumab rituximab-treated rheumatic diseases high-dose glucocorticoid bridging biologicals targetspecific pathways open-label extension study anti-tnf therapy van vollenhoven rf histone deacetylase inhibitor treatment-refractory rheumatoid arthritis b-cell therapies full article pdf bmc med genomics modern pharmacologic therapies privacy choices/manage cookies van der heijde targeted dmards tnf-α inhibitors cell-based therapy ved chaturvedi biologic-naïve ra patients anti-tnf therapie anti-drug antibodies long-term persistence provide comprehensive data methotrexate-related adverse events smolen js cellular biochemistry aims joint structural damage resuming biologic dmards macrophage il-6 production biological therapy placebo-controlled trial

Questions {❓}

Nestorov I (2005) Clinical pharmacokinetics of TNF antagonists: how do they differ?
Van Vollenhoven R (2019) Treat-to-target in rheumatoid arthritis—are we there yet?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Rheumatoid arthritis: advances in treatment strategies
         description:Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to heightened autoimmune response at the articular sites. Worldwide annual incidence and prevalence rate of RA is 3 cases per 10,000 population and 1%, respectively. Several genetic and environmental (microbiota, smoking, infectious agents) factors contribute to its pathogenesis. Although convention treatment strategies, predominantly Disease Modifying Anti Rheumatic Drugs (DMARDs) and Glucocorticoids (GC), are unchanged as the primary line of treatment; novel strategies consisting of biological DMARDs, are being developed and explored. Personalized approaches using biologicals targetspecific pathways associated with disease progression. However, considering the economic burden and side-effects associated with these, there is an unmet need on strategies for early stratification of the inadequate responders with cDMARDs. As RA is a complex disease with a variable remission rate, it is important not only to evaluate the current status of drugs in clinical practice but also those with the potential of personalised therapeutics. Here, we provide comprehensive data on the treatment strategies in RA, including studies exploring various combination strategies in clinical trials. Our systematic analysis of current literature found that conventional DMARDs along with glucocorticoid may be best suited for early RA cases and a combination of conventional and targeted DMARDs could be effective for treating seronegative patients with moderate to high RA activity. Clinical trials with insufficient responders to Methotrexate suggest that adding biologicals may help in such cases. However, certain adverse events associated with the current therapy advocate exploring novel therapeutic approaches such as gene therapy, mesenchymal stem cell therapy in future.
         datePublished:2022-06-21T00:00:00Z
         dateModified:2022-06-21T00:00:00Z
         pageStart:69
         pageEnd:88
         sameAs:https://doi.org/10.1007/s11010-022-04492-3
         keywords:
            Rheumatoid arthritis
            DMARDs
            Biologicals
            Therapy
            Clinical trial
            Biochemistry
            general
            Cardiology
            Cancer Research
            Medical Biochemistry
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig4_HTML.png
         isPartOf:
            name:Molecular and Cellular Biochemistry
            issn:
               1573-4919
               0300-8177
            volumeNumber:478
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Peeyush Prasad
               affiliation:
                     name:Sir Ganga Ram Hospital
                     address:
                        name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Sneha Verma
               affiliation:
                     name:Sir Ganga Ram Hospital
                     address:
                        name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Surbhi
               affiliation:
                     name:Sir Ganga Ram Hospital
                     address:
                        name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Nirmal Kumar Ganguly
               affiliation:
                     name:Sir Ganga Ram Hospital
                     address:
                        name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Ved Chaturvedi
               affiliation:
                     name:Sir Ganga Ram Hospital
                     address:
                        name:Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, New Delhi, India
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Shivani Arora Mittal
               url:http://orcid.org/0000-0001-9734-3488
               affiliation:
                     name:Sir Ganga Ram Hospital
                     address:
                        name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Rheumatoid arthritis: advances in treatment strategies
      description:Rheumatoid arthritis (RA) is characterised by severe joint and bone damage due to heightened autoimmune response at the articular sites. Worldwide annual incidence and prevalence rate of RA is 3 cases per 10,000 population and 1%, respectively. Several genetic and environmental (microbiota, smoking, infectious agents) factors contribute to its pathogenesis. Although convention treatment strategies, predominantly Disease Modifying Anti Rheumatic Drugs (DMARDs) and Glucocorticoids (GC), are unchanged as the primary line of treatment; novel strategies consisting of biological DMARDs, are being developed and explored. Personalized approaches using biologicals targetspecific pathways associated with disease progression. However, considering the economic burden and side-effects associated with these, there is an unmet need on strategies for early stratification of the inadequate responders with cDMARDs. As RA is a complex disease with a variable remission rate, it is important not only to evaluate the current status of drugs in clinical practice but also those with the potential of personalised therapeutics. Here, we provide comprehensive data on the treatment strategies in RA, including studies exploring various combination strategies in clinical trials. Our systematic analysis of current literature found that conventional DMARDs along with glucocorticoid may be best suited for early RA cases and a combination of conventional and targeted DMARDs could be effective for treating seronegative patients with moderate to high RA activity. Clinical trials with insufficient responders to Methotrexate suggest that adding biologicals may help in such cases. However, certain adverse events associated with the current therapy advocate exploring novel therapeutic approaches such as gene therapy, mesenchymal stem cell therapy in future.
      datePublished:2022-06-21T00:00:00Z
      dateModified:2022-06-21T00:00:00Z
      pageStart:69
      pageEnd:88
      sameAs:https://doi.org/10.1007/s11010-022-04492-3
      keywords:
         Rheumatoid arthritis
         DMARDs
         Biologicals
         Therapy
         Clinical trial
         Biochemistry
         general
         Cardiology
         Cancer Research
         Medical Biochemistry
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11010-022-04492-3/MediaObjects/11010_2022_4492_Fig4_HTML.png
      isPartOf:
         name:Molecular and Cellular Biochemistry
         issn:
            1573-4919
            0300-8177
         volumeNumber:478
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Peeyush Prasad
            affiliation:
                  name:Sir Ganga Ram Hospital
                  address:
                     name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Sneha Verma
            affiliation:
                  name:Sir Ganga Ram Hospital
                  address:
                     name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Surbhi
            affiliation:
                  name:Sir Ganga Ram Hospital
                  address:
                     name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Nirmal Kumar Ganguly
            affiliation:
                  name:Sir Ganga Ram Hospital
                  address:
                     name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Ved Chaturvedi
            affiliation:
                  name:Sir Ganga Ram Hospital
                  address:
                     name:Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, New Delhi, India
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Shivani Arora Mittal
            url:http://orcid.org/0000-0001-9734-3488
            affiliation:
                  name:Sir Ganga Ram Hospital
                  address:
                     name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Molecular and Cellular Biochemistry
      issn:
         1573-4919
         0300-8177
      volumeNumber:478
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Sir Ganga Ram Hospital
      address:
         name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
         type:PostalAddress
      name:Sir Ganga Ram Hospital
      address:
         name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
         type:PostalAddress
      name:Sir Ganga Ram Hospital
      address:
         name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
         type:PostalAddress
      name:Sir Ganga Ram Hospital
      address:
         name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
         type:PostalAddress
      name:Sir Ganga Ram Hospital
      address:
         name:Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, New Delhi, India
         type:PostalAddress
      name:Sir Ganga Ram Hospital
      address:
         name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Peeyush Prasad
      affiliation:
            name:Sir Ganga Ram Hospital
            address:
               name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
               type:PostalAddress
            type:Organization
      name:Sneha Verma
      affiliation:
            name:Sir Ganga Ram Hospital
            address:
               name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
               type:PostalAddress
            type:Organization
      name:Surbhi
      affiliation:
            name:Sir Ganga Ram Hospital
            address:
               name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
               type:PostalAddress
            type:Organization
      name:Nirmal Kumar Ganguly
      affiliation:
            name:Sir Ganga Ram Hospital
            address:
               name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
               type:PostalAddress
            type:Organization
      name:Ved Chaturvedi
      affiliation:
            name:Sir Ganga Ram Hospital
            address:
               name:Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, New Delhi, India
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Shivani Arora Mittal
      url:http://orcid.org/0000-0001-9734-3488
      affiliation:
            name:Sir Ganga Ram Hospital
            address:
               name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
      name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
      name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
      name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
      name:Department of Rheumatology and Clinical Immunology, Sir Ganga Ram Hospital, New Delhi, India
      name:Department of Research, Sir Ganga Ram Hospital, New Delhi, India
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(403)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.4s.

LINK . SPRINGER . COM {}